Clinical outcomes of vertical bone augmentation to enable dental implant placement: a systematic review

2008 ◽  
Vol 35 ◽  
pp. 203-215 ◽  
Author(s):  
Isabella Rocchietta ◽  
Filippo Fontana ◽  
Massimo Simion
2010 ◽  
Vol 46 (1) ◽  
pp. 43-53 ◽  
Author(s):  
Kengo Shimono ◽  
Masamitsu Oshima ◽  
Hikaru Arakawa ◽  
Aya Kimura ◽  
Kumiko Nawachi ◽  
...  

2019 ◽  
Vol 46 ◽  
pp. 257-276 ◽  
Author(s):  
Daniel S. Thoma ◽  
Stefan P. Bienz ◽  
Elena Figuero ◽  
Ronald E. Jung ◽  
Ignacio Sanz-Martín

Author(s):  
Judd Sher ◽  
Kate Kirkham-Ali ◽  
Denny Luo ◽  
Catherine Miller ◽  
Dileep Sharma

The present systematic review evaluates the safety of placing dental implants in patients with a history of antiresorptive or antiangiogenic drug therapy. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed. PubMed, Cochrane Central Register of Controlled Trials, Scopus, Web of Science, and OpenGrey databases were used to search for clinical studies (English only) to July 16, 2019. Study quality was assessed regarding randomization, allocation sequence concealment, blinding, incomplete outcome data, selective outcome reporting, and other biases using a modified Newcastle-Ottawa scale and the Joanna Briggs Institute critical appraisal checklist for case series. A broad search strategy resulted in the identification of 7542 studies. There were 28 studies reporting on bisphosphonates (5 cohort, 6 case control, and 17 case series) and one study reporting on denosumab (case series) that met the inclusion criteria and were included in the qualitative synthesis. The quality assessment revealed an overall moderate quality of evidence among the studies. Results demonstrated that patients with a history of bisphosphonate treatment for osteoporosis are not at increased risk of implant failure in terms of osseointegration. However, all patients with a history of bisphosphonate treatment, whether taken orally for osteoporosis or intravenously for malignancy, appear to be at risk of ‘implant surgery-triggered’ MRONJ. In contrast, the risk of MRONJ in patients treated with denosumab for osteoporosis was found to be negligible. In conclusion, general and specialist dentists should exercise caution when planning dental implant therapy in patients with a history of bisphosphonate and denosumab drug therapy. Importantly, all patients with a history of bisphosphonates are at risk of MRONJ, necessitating this to be included in the informed consent obtained prior to implant placement. The James Cook University College of Medicine and Dentistry Honours program and the Australian Dental Research Foundation Colin Cormie Grant were the primary sources of funding for this systematic review.


2018 ◽  
Vol 90 (5) ◽  
pp. 493-506 ◽  
Author(s):  
Seyed Hossein Bassir ◽  
Karim El Kholy ◽  
Chia‐Yu Chen ◽  
Kyu Ha Lee ◽  
Giuseppe Intini

2006 ◽  
Vol 20 (4) ◽  
pp. 325-339 ◽  
Author(s):  
Antonietta M. Gatti ◽  
Leopoldo A. Simonetti ◽  
Emanuela Monari ◽  
Stefano Guidi ◽  
David Greenspan

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Basim E. S. Dawoud ◽  
Samuel Kent ◽  
Oliver Tabbenor ◽  
Pynadath George ◽  
Jagtar Dhanda

Abstract Background Dental implant placement is safe and predictable, yet optimal management of anticoagulated patients remains controversial. Whilst cessation of anticoagulation pre-operatively should decrease risks of bleeding, risk of thrombosis increases. We aim to define risk of bleeding in patients on oral anticoagulation who are undergoing dental implant placement, in order to establish best management. Methods This systematic review is registered with the National Institute for Health Research (NIHR) PROSPERO database (Registration No: CRD42021233929). We performed a systematic review as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance. Studies were identified using an agreed search strategy within the OVID Gateway (this included Pubmed, MEDLINE, Cochrane Collaborative). Studies assessing bleeding complications in patients who were undergoing dental implant placement were selected. The primary outcome was bleeding events in anticoagulated patients undergoing dental implant placement. Secondary outcomes included any complication requiring further intervention. Results We identified 182 studies through screening, and after review of titles and abstracts reduced this to 8 studies. In these studies, 1467 participants received at least 2366 implants. Studies were analysed for quality using the ROBINS-I risk of bias tool. Four studies were retrospective case reviews, and four were prospective reviews, three of which also blinded the operator to anticoagulation status. There was significant heterogeneity between the included studies. Meta-analysis showed an increased risk of bleeding (RR, 2.30; 95% CI, 1.25-4.24 p = 0.37 I = 7%) when implants were placed in the presence of anticoagulation however these were not clinically significant haemorrhagic events. Conclusion The continuation of anticoagulants peri-operatively during dental implant surgery does increase the risk of clinically non-significant peri- and post-operative bleeding. Dental implant surgery encompasses a broad spectrum of procedures ranging from minor to more invasive surgery with simple local haemostatic measures mitigating the risk of bleeding. The decision to discontinue anticoagulants prior to dental implant surgery must consider patient and surgical factors with the clinician undertaking a risk-balance assessment.


2019 ◽  
Vol 46 (3) ◽  
pp. 382-395 ◽  
Author(s):  
Mario Romandini ◽  
Ilaria De Tullio ◽  
Francesca Congedi ◽  
Zamira Kalemaj ◽  
Mattia D‘Ambrosio ◽  
...  

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Luis Miguel Sáez-Alcaide ◽  
Jorge Cortés-Bretón Brinkmann ◽  
Luis Sánchez-Labrador ◽  
Fabián Pérez-González ◽  
Pedro Molinero-Mourelle ◽  
...  

Abstract Background Dimensional changes after dental extraction frequently lead to situations in which bone augmentation procedures are required prior to dental implant placement. Bone ring technique (BRT) has been described as a one-stage approach to restore vertical alveolar ridge defects, in which an autogenous or allogeneic cortico-cancellous bone block graft is stabilized with a dental implant inserted simultaneously. The objective of this systematic review was to evaluate the clinical performance of BRT. Materials and methods This review was conducted according to PRISMA guidelines. An electronic search was conducted in four databases: (1) The National Library of Medicine (MEDLINE/PubMed) via Ovid; (2) Web of Science (WOS); (3) SCOPUS; and (4) Cochrane Central Register of Controlled Trials (CENTRAL). The Newcastle-Ottawa Quality Assessment Scale and The Joanna Briggs Institute Critical Appraisal tool were used to assess the quality of evidence in the studies reviewed. Results Sixteen studies with a total of 186 patients treated with 219 bone rings bocks were included in the review. The studies showed a mean bone gain of 4.94 mm, mean bone resorption of 0.83 mm, and mean marginal bone loss of 0.57 mm after a mean follow-up period of 13.35 months. A mean bone ring survival rate of 97.26% and implant survival rate of 94.97% were recorded. Conclusions BRT would appear to be an adequate alternative technique for restoring single vertical alveolar ridge defects with simultaneous dental implant placement. However, further studies comparing this technique with other vertical ridge augmentation procedures in different clinical scenarios are needed to confirm the present results.


Sign in / Sign up

Export Citation Format

Share Document